Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G Raverot, F Castinetti, E Jouanneau… - Clinical …, 2012 - Wiley Online Library
Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …
被引用次数：173 相关文章

[引用][C] Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G Raverot, F Castinetti, E Jouanneau, I Morange… - Clinical …, 2012 - cir.nii.ac.jp
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide
treatment | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G Raverot, F Castinetti, E Jouanneau, I Morange… - Clinical …, 2012 - infona.pl
Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

G Raverot, F Castinetti, E Jouanneau, I Morange… - Clinical …, 2012 - hal.science
Pituitary carcinomas are rare, accounting for about 0* 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

G Raverot, F Castinetti, E Jouanneau… - Clinical …, 2012 - europepmc.org
Pituitary carcinomas are rare, accounting for about 0.2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

[引用][C] Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G RAVEROT, F CASTINETTI… - Clinical …, 2012 - pascal-francis.inist.fr
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide
treatment CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G Raverot, F Castinetti, E Jouanneau… - Clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Pituitary carcinomas are rare, accounting for about 0.2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

[引用][C] Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G RAVEROT - Clin Endocrinol (Oxf), 2012 - cir.nii.ac.jp

[引用][C] Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

G RAVEROT, F CASTINETTI, E JOUANNEAU… - Clinical …, 2012 - Blackwell